Kazia Therapeutics Limited (KZIA)

Market Cap	21.02M
Revenue (ttm)	10.89M
Net Income (ttm)	-10.77M
Shares Out	18.12M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,661
Open	1.16
Previous Close	1.13
Day's Range	1.14 - 1.21
52-Week Range	1.04 - 12.28
Beta	2.88
Analysts	Buy
Price Target	3.24 (+179.3%)
Earnings Date	Oct 6, 2022

About KZIA

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Austr...

• Industry: Biotechnology
• IPO Date: Jan 6, 1999
• Employees: 2,021
• Stock Exchange: NASDAQ
• Ticker Symbol: KZIA

Full Company Profile

Financial Performance

In 2021, KZIA's revenue was 15.23 million, an increase of 1,335.16% compared to the previous year's 1.06 million. Losses were -8.42 million, -32.45% less than in 2020.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for KZIA stock is "Buy." The 12-month stock price forecast is 3.24, which is an increase of 179.31% from the latest price.

Price Target

$3.24

(179.31% upside)

Analyst Consensus: Buy

Stock Forecasts